1. Home
  2. EDRY vs CHRS Comparison

EDRY vs CHRS Comparison

Compare EDRY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EuroDry Ltd.

EDRY

EuroDry Ltd.

SELL

Current Price

$33.32

Market Cap

139.6M

ML Signal

SELL

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$0.37

Market Cap

159.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDRY
CHRS
Founded
2018
2010
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.6M
159.1M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
EDRY
CHRS
Price
$33.32
$0.37
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
★ $55.67
$7.25
AVG Volume (30 Days)
79.7K
★ 2.6M
Earning Date
11-11-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 472.00
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$42.38
$34.48
Revenue Next Year
$14.31
$54.28
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$12.30
$0.37
52 Week High
$73.07
$2.62

Technical Indicators

Market Signals
Indicator
EDRY
CHRS
Relative Strength Index (RSI) 35.35 23.34
Support Level $19.19 N/A
Resistance Level $46.44 $1.53
Average True Range (ATR) 3.88 0.07
MACD -0.09 -0.03
Stochastic Oscillator 10.64 1.64

Price Performance

Historical Comparison
EDRY
CHRS

About EDRY EuroDry Ltd.

EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: